Published in Liver Transpl on February 01, 2006
Pharmacokinetics of cyclosporine A after massive hepatectomy: a hint for small-for-size graft in living donor liver transplantation. Dig Dis Sci (2007) 0.79
Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. Eur J Clin Pharmacol (2011) 0.78
In vitro immune cell monitoring as a guide for long-term immunosuppression in adult liver transplant recipients. Korean J Hepatobiliary Pancreat Surg (2015) 0.75
Optimal administration of tacrolimus in reduced-size liver. Dig Dis Sci (2008) 0.75
Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med (2006) 4.53
ATP hydrolysis is required for cohesin's association with chromosomes. Curr Biol (2003) 2.69
The utility of marginal donors in liver transplantation. Liver Transpl (2003) 2.49
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.41
Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet (2005) 2.39
Nonalcoholic steatohepatitis in donors for living donor liver transplantation. Transplantation (2007) 2.25
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl (2007) 2.09
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol (2007) 2.05
Human Scc4 is required for cohesin binding to chromatin, sister-chromatid cohesion, and mitotic progression. Curr Biol (2006) 2.04
Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells. Int Immunol (2004) 2.04
Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. Circ J (2015) 2.03
Portal pressure <15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl (2010) 2.02
Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet (2005) 1.96
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation? Surgery (2010) 1.82
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol (2009) 1.82
Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl (2006) 1.81
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
Auxiliary partial orthotopic living donor liver transplantation: Kyoto University experience. Am J Transplant (2005) 1.70
SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J Am Soc Nephrol (2009) 1.70
Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl (2012) 1.67
Bridging use of plasma exchange and continuous hemodiafiltration before living donor liver transplantation in fulminant Wilson's disease. Intern Med (2003) 1.64
Left-sided grafts for living-donor liver transplantation and split grafts for deceased-donor liver transplantation: their impact on long-term survival. Clin Res Hepatol Gastroenterol (2011) 1.63
Living donor liver transplantation with reduced monosegments for neonates and small infants. Transplantation (2007) 1.61
The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation (2008) 1.61
Comprehensive and innovative techniques for liver transplantation in rats: a surgical guide. World J Gastroenterol (2010) 1.57
Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol (2009) 1.53
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl (2006) 1.52
Noninvasive evaluation of graft steatosis in living donor liver transplantation. Transplantation (2004) 1.49
Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver. J Gastroenterol Hepatol (2009) 1.48
Resistance to parathyroid hormone in two patients with familial intrahepatic cholestasis: possible involvement of the ATP8B1 gene in calcium regulation via parathyroid hormone. J Pediatr Gastroenterol Nutr (2004) 1.48
Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl (2006) 1.48
Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. Transplantation (2002) 1.48
Identification and comparative functional characterization of a new human riboflavin transporter hRFT3 expressed in the brain. J Nutr (2010) 1.47
Long-term quality of life of donors after living donor liver transplantation. Liver Transpl (2012) 1.47
Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol (2011) 1.47
Pre- and perioperative factors affecting infection after living donor liver transplantation. Nutrition (2012) 1.46
Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation. Liver Transpl (2003) 1.46
Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications. Transplantation (2003) 1.45
Living-donor liver transplantation with monosegments. Transplantation (2003) 1.45
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol (2012) 1.43
Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg (2003) 1.42
Identification of a subunit of a novel Kleisin-beta/SMC complex as a potential substrate of protein phosphatase 2A. Curr Biol (2003) 1.41
Shugoshin-PP2A counteracts casein-kinase-1-dependent cleavage of Rec8 by separase. Nat Cell Biol (2010) 1.40
Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant (2004) 1.40
Varicose bleeding after liver transplantation in a patient with severe portosystemic shunts. J Gastroenterol (2003) 1.39
Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. Am J Physiol Cell Physiol (2008) 1.38
Is MIBG a substrate of P-glycoprotein? Eur J Nucl Med Mol Imaging (2006) 1.37
Duct-to-duct biliary reconstruction in living donor liver transplantation utilizing right lobe graft. Ann Surg (2002) 1.37
Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol (2007) 1.35
Biliary reconstruction in right lobe living-donor liver transplantation: Comparison of different techniques in 321 recipients. Ann Surg (2006) 1.35
C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics (2002) 1.33
Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University. Liver Transpl (2005) 1.32
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res (2007) 1.32
Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Hum Mutat (2011) 1.31
Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol (2004) 1.29
Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol (2005) 1.28